sarcoidosis

The Finest Immune Map of the Sarcoid Lung Explains Why Its Targeted Drugs Keep Failing

National Jewish Health charted more than 150,000 immune cells from sixteen sarcoidosis patients and found a disease with too many moving parts for any single drug to switch off. The targeted therapy that got furthest had already failed Phase 3 and erased 83 percent of its maker's value.